A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
Stopped Absence of patient's recruitment in the study due to administrative reasons
Conditions
Interventions
- DRUG: bevacizumab [Avastin]
- DRUG: paclitaxel
Sponsor
Hoffmann-La Roche